Skip to main content
. 2017 Apr 18;18(6):962–981. doi: 10.15252/embr.201643519

Figure 8. Co‐application of anti‐TNFα antibody prevents Aβ3(pE)‐42‐caused synaptic loss and decrease in pCREB .

Figure 8

  1. Bar plots representing mean synapse density after treatment with anti‐TNFα antibody alone or with Aβ1‐42 or Aβ3(pE)‐42 co‐application. Anti‐TNFα antibody fully prevents synaptic loss only in case of Aβ3(pE)‐42. In case of Aβ1‐42 application, the antibody treatment provides a partial rescue. Dashed lines indicate mean synapse density from Fig 1B: black, control; grey, Aβ1‐42 treatment; red, Aβ3(pE)‐42 treatment. n corresponds to the number of nuclei from different neurons analysed from at least four independent coverslips and at least two independent cell cultures.
  2. Confocal images of representative dendrites stained for Homer1, Synaptophysin and MAP2. Scale bar, 5 μm.
  3. Anti‐TNFα antibody does not cause CREB shut‐off and prevents Aβ1‐42‐ or Aβ3(pE)‐42‐caused decrease in nuclear pCREB levels. Original pixel intensities from 0 to 255 are represented as a gradient lookup table. Scale bar, 10 μm.
  4. Bar plot representing mean nuclear pCREB staining intensity. n corresponds to the number of nuclei from different neurons analysed from at least four independent coverslips and at least two independent cell cultures.
Data information: P‐values versus control, by one‐way ANOVA. Data are presented as the mean ± s.e.m.